Epithelial Ovarian Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：164頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Epithelial Ovarian Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Epithelial Ovarian Cancer - Pipeline Review, H1 2014’, provides an overview of the Epithelial Ovarian Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Epithelial Ovarian Cancer - Pipeline Review, H1 2014’, provides an overview of the Epithelial Ovarian Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Epithelial Ovarian Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Epithelial Ovarian Cancer - Overview 11
Pipeline Products for Epithelial Ovarian Cancer - Comparative Analysis 12
Epithelial Ovarian Cancer - Therapeutics under Development by Companies 13
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 16
Epithelial Ovarian Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Epithelial Ovarian Cancer - Products under Development by Companies 21
Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 22
Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 23
Boehringer Ingelheim GmbH 23
Amgen Inc. 24
Oxford BioMedica plc 25
Millennium Pharmaceuticals, Inc. 26
ImmunoGen, Inc. 27
Bayer AG 28
Pharmacyclics, Inc. 29
Prima BioMed Ltd. 30
Synta Pharmaceuticals Corp. 31
Oasmia Pharmaceutical AB 32
Glycotope GmbH 33
TRION Pharma GmbH 34
BioNumerik Pharmaceuticals, Inc. 35
CerRx, Inc. 36
Immunotope, Inc. 37
Pharma Mar, S.A. 38
VentiRx Pharmaceuticals, Inc. 39
Clovis Oncology, Inc. 40
Recepta Biopharma S.A. 41
California Stem Cell, Inc. 42
EGEN, Inc. 43
AbbVie Inc. 44
Sotio a.s. 45
Epithelial Ovarian Cancer - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Target 47
Assessment by Mechanism of Action 51
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
trebananib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
paclitaxel - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CVac - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
cositecan - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
trabectedin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
rucaparib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
sorafenib tosylate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
alisertib - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PankoMab GEX - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
elesclomol - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TroVax - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
nintedanib - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
catumaxomab - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
VTX-2337 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
RebmAb-100 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
EGEN-001 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
DCVAC/OvCa - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Cancer Stem Cell Therapy - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
fenretinide - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ganetespib - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
DC-006 Vaccine - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
abexinostat hydrochloride - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
nintedanib - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
IMT-1012 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
HER-2/Neu Specific T Cells - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
MV-NIS Vaccine - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
IMGN-853 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Procure - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
DCVAC/OvCa - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Fe-SP - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
ABT-898 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
NERX-505X - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
NERX-313E - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Epithelial Ovarian Cancer - Recent Pipeline Updates 125
Epithelial Ovarian Cancer - Dormant Projects 155
Epithelial Ovarian Cancer - Discontinued Products 156
Epithelial Ovarian Cancer - Product Development Milestones 157
Featured News & Press Releases 157
Jul 03, 2013: Prima BioMed Activates Study Sites in Germany and Multiple European Countries for CANVAS Clinical Trial 157
Jun 01, 2013: GSK's Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer 157
Apr 17, 2013: Prima Biomed Receives Japanese Patent For CVac 158
Apr 10, 2013: MEI Pharma Presents Data On Mitochondrial Inhibitor Drug Candidate ME-344 At AACR Annual Meeting 2013 158
Mar 19, 2013: Prima BioMed Receives €3.8m Grant From Saxony Development Bank To Support Development Of CVac 159
Feb 27, 2013: Prima Biomed Commences Phase II/III Clinical Trial Of CVac In Europe 159
Feb 04, 2013: Prima BioMed To Present Data On R&D Of CVac At ISCT Annual Meeting 160
Jan 10, 2013: Morphotek Announces Top-Line Results Of Phase III Study Of Farletuzumab In Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer 160
Nov 14, 2012: Prima BioMed Releases Interim Immune Monitoring Data From CVac Phase II Clinical Trial 161
Oct 15, 2012: Prima BioMed Announces Positive Interim Data From CAN-003 Trial Of CVac For Ovarian Cancer 162
Appendix 163
Methodology 163
Coverage 163
Secondary Research 163
Primary Research 163
Expert Panel Validation 163
Contact Us 164
Disclaimer 164
List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H1 2014 11
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Investigation by Universities/Institutes, H1 2014 22
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 23
Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H1 2014 24
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica plc, H1 2014 25
Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 26
Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H1 2014 27
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H1 2014 28
Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H1 2014 29
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H1 2014 30
Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 31
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2014 32
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2014 33
Epithelial Ovarian Cancer - Pipeline by TRION Pharma GmbH, H1 2014 34
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2014 35
Epithelial Ovarian Cancer - Pipeline by CerRx, Inc., H1 2014 36
Epithelial Ovarian Cancer - Pipeline by Immunotope, Inc., H1 2014 37
Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H1 2014 38
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2014 39
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2014 40
Epithelial Ovarian Cancer - Pipeline by Recepta Biopharma S.A., H1 2014 41
Epithelial Ovarian Cancer - Pipeline by California Stem Cell, Inc., H1 2014 42
Epithelial Ovarian Cancer - Pipeline by EGEN, Inc., H1 2014 43
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H1 2014 44
Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H1 2014 45
Assessment by Monotherapy Products, H1 2014 46
Number of Products by Stage and Target, H1 2014 49
Number of Products by Stage and Mechanism of Action, H1 2014 53
Number of Products by Stage and Route of Administration, H1 2014 55
Number of Products by Stage and Molecule Type, H1 2014 57
Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2014 125
Epithelial Ovarian Cancer - Dormant Projects, H1 2014 155
Epithelial Ovarian Cancer - Discontinued Products, H1 2014 156
List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H1 2014 11
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Assessment by Monotherapy Products, H1 2014 46
Number of Products by Top 10 Target, H1 2014 47
Number of Products by Stage and Top 10 Target, H1 2014 48
Number of Products by Top 10 Mechanism of Action, H1 2014 51
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 52
Number of Products by Top 10 Route of Administration, H1 2014 54
Number of Products by Stage and Top 10 Route of Administration, H1 2014 55
Number of Products by Top 10 Molecule Type, H1 2014 56
Number of Products by Stage and Top 10 Molecule Type, H1 2014 57
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Epithelial Ovarian Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Epithelial Ovarian Cancer - Overview 11
Pipeline Products for Epithelial Ovarian Cancer - Comparative Analysis 12
Epithelial Ovarian Cancer - Therapeutics under Development by Companies 13
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 16
Epithelial Ovarian Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Epithelial Ovarian Cancer - Products under Development by Companies 21
Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 22
Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 23
Boehringer Ingelheim GmbH 23
Amgen Inc. 24
Oxford BioMedica plc 25
Millennium Pharmaceuticals, Inc. 26
ImmunoGen, Inc. 27
Bayer AG 28
Pharmacyclics, Inc. 29
Prima BioMed Ltd. 30
Synta Pharmaceuticals Corp. 31
Oasmia Pharmaceutical AB 32
Glycotope GmbH 33
TRION Pharma GmbH 34
BioNumerik Pharmaceuticals, Inc. 35
CerRx, Inc. 36
Immunotope, Inc. 37
Pharma Mar, S.A. 38
VentiRx Pharmaceuticals, Inc. 39
Clovis Oncology, Inc. 40
Recepta Biopharma S.A. 41
California Stem Cell, Inc. 42
EGEN, Inc. 43
AbbVie Inc. 44
Sotio a.s. 45
Epithelial Ovarian Cancer - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Target 47
Assessment by Mechanism of Action 51
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
trebananib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
paclitaxel - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CVac - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
cositecan - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
trabectedin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
rucaparib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
sorafenib tosylate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
alisertib - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PankoMab GEX - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
elesclomol - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TroVax - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
nintedanib - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
catumaxomab - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
VTX-2337 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
RebmAb-100 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
EGEN-001 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
DCVAC/OvCa - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Cancer Stem Cell Therapy - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
fenretinide - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ganetespib - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
DC-006 Vaccine - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
abexinostat hydrochloride - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
nintedanib - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
IMT-1012 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
HER-2/Neu Specific T Cells - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
MV-NIS Vaccine - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
IMGN-853 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Procure - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
DCVAC/OvCa - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Fe-SP - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
ABT-898 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
NERX-505X - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
NERX-313E - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Epithelial Ovarian Cancer - Recent Pipeline Updates 125
Epithelial Ovarian Cancer - Dormant Projects 155
Epithelial Ovarian Cancer - Discontinued Products 156
Epithelial Ovarian Cancer - Product Development Milestones 157
Featured News & Press Releases 157
Jul 03, 2013: Prima BioMed Activates Study Sites in Germany and Multiple European Countries for CANVAS Clinical Trial 157
Jun 01, 2013: GSK's Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer 157
Apr 17, 2013: Prima Biomed Receives Japanese Patent For CVac 158
Apr 10, 2013: MEI Pharma Presents Data On Mitochondrial Inhibitor Drug Candidate ME-344 At AACR Annual Meeting 2013 158
Mar 19, 2013: Prima BioMed Receives €3.8m Grant From Saxony Development Bank To Support Development Of CVac 159
Feb 27, 2013: Prima Biomed Commences Phase II/III Clinical Trial Of CVac In Europe 159
Feb 04, 2013: Prima BioMed To Present Data On R&D Of CVac At ISCT Annual Meeting 160
Jan 10, 2013: Morphotek Announces Top-Line Results Of Phase III Study Of Farletuzumab In Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer 160
Nov 14, 2012: Prima BioMed Releases Interim Immune Monitoring Data From CVac Phase II Clinical Trial 161
Oct 15, 2012: Prima BioMed Announces Positive Interim Data From CAN-003 Trial Of CVac For Ovarian Cancer 162
Appendix 163
Methodology 163
Coverage 163
Secondary Research 163
Primary Research 163
Expert Panel Validation 163
Contact Us 164
Disclaimer 164
List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H1 2014 11
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Investigation by Universities/Institutes, H1 2014 22
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 23
Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H1 2014 24
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica plc, H1 2014 25
Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 26
Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H1 2014 27
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H1 2014 28
Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H1 2014 29
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H1 2014 30
Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 31
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2014 32
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2014 33
Epithelial Ovarian Cancer - Pipeline by TRION Pharma GmbH, H1 2014 34
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2014 35
Epithelial Ovarian Cancer - Pipeline by CerRx, Inc., H1 2014 36
Epithelial Ovarian Cancer - Pipeline by Immunotope, Inc., H1 2014 37
Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H1 2014 38
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2014 39
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2014 40
Epithelial Ovarian Cancer - Pipeline by Recepta Biopharma S.A., H1 2014 41
Epithelial Ovarian Cancer - Pipeline by California Stem Cell, Inc., H1 2014 42
Epithelial Ovarian Cancer - Pipeline by EGEN, Inc., H1 2014 43
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H1 2014 44
Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H1 2014 45
Assessment by Monotherapy Products, H1 2014 46
Number of Products by Stage and Target, H1 2014 49
Number of Products by Stage and Mechanism of Action, H1 2014 53
Number of Products by Stage and Route of Administration, H1 2014 55
Number of Products by Stage and Molecule Type, H1 2014 57
Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2014 125
Epithelial Ovarian Cancer - Dormant Projects, H1 2014 155
Epithelial Ovarian Cancer - Discontinued Products, H1 2014 156
List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H1 2014 11
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Assessment by Monotherapy Products, H1 2014 46
Number of Products by Top 10 Target, H1 2014 47
Number of Products by Stage and Top 10 Target, H1 2014 48
Number of Products by Top 10 Mechanism of Action, H1 2014 51
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 52
Number of Products by Top 10 Route of Administration, H1 2014 54
Number of Products by Stage and Top 10 Route of Administration, H1 2014 55
Number of Products by Top 10 Molecule Type, H1 2014 56
Number of Products by Stage and Top 10 Molecule Type, H1 2014 57
